| [1] |
Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study[J]. Ann Intern Med, 2005, 143(10):697-706.
|
| [2] |
Lindqvist P, Dahlbäck B, Marŝl K. Thrombotic risk during pregnancy: a population study[J]. Obstet Gynecol, 1999, 94(4):595-599.
|
| [3] |
James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality[J]. Am J Obstet Gynecol, 2006, 194(5):1311-1315.
|
| [4] |
Rodger M. Evidence base for the management of venous thromboembolism in pregnancy[J]. Hematology Am Soc Hematol Educ Program, 2010, 2010:173-180.
|
| [5] |
Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review[J]. Br J Haematol, 2006, 132(2):171-196.
|
| [6] |
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J]. J Thromb Haemost, 2006, 4(2):295-306.
|
| [7] |
Bates SM. Preventing thrombophilia-related complications of pregnancy: an update[J]. Expert Rev Hematol, 2013, 6(3):287-300.
|
| [8] |
Gary T, Belaj K, Bruckenberger R, et al. Primary antiphospholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism[J]. Obesity (Silver Spring), 2013, 21(9): E463-E466.
|
| [9] |
Urbanus RT, de Groot PG. Antiphospholipid antibodies--we are not quite there yet[J]. Blood Rev, 2011, 25(2):97-106.
|
| [10] |
Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature[J]. Blood, 2003, 101(5):1827-1832.
|
| [11] |
Lubbe WF, Butler WS, Palmer SJ, et al. Lupus anticoagulant in pregnancy[J]. Br J Obstet Gynaecol, 1984, 91(4):357-363.
|
| [12] |
张蕾，付锦华，曹双元. 血中狼疮抗凝物的含量与自然流产的关系[J]. 中外医学研究，2011, 9(1):11-12.
|
| [13] |
Green D, Hougie C, Kazmier FJ, et al. Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the " lupus" anticoagulant. Thromb Haemost, 1983, 49(2):144-146.
|
| [14] |
Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost, 2009, 7(10):1737-1740.
|
| [15] |
Dembitzer FR, Ledford Kraemer MR, Meijer P, et al. Lupus anticoagulant testing: performance and practices by north american clinical laboratories[J]. Am J Clin Pathol, 2010, 134(5):764-773.
|
| [16] |
Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing[J]. Semin Thromb Hemost, 2013, 39(3):267-271.
|
| [17] |
Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment[J]. Obstet Gynecol, 2002, 100(3):408-413.
|
| [18] |
Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor[J]. Lancet, 1990, 335(8705):1544-1547.
|
| [19] |
潘婉仪，丁海明，周华友. 抗β2-糖蛋白Ⅰ抗体与先兆流产的关系[J]. 检验医学，2010, 25(7):569-571.
|
| [20] |
Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure[J]. EMBO J, 1999, 18(19):5166-5174.
|
| [21] |
Schousboe I. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway[J]. Blood, 1985, 66(5):1086-1091.
|
| [22] |
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4(2):295-306.
|
| [23] |
Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo[J]. Circulation, 1999, 99(15):1997-2002.
|
| [24] |
Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome[J]. J Thromb Haemost, 2006, 4(11):2461-2419.
|
| [25] |
Joseph JE, Harrison P, Mackie IJ, et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis[J]. Br J Haematol, 2001, 115(2):451-459.
|
| [26] |
Satta N, Kruithof EK, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies[J]. Blood, 2011, 117(20):5523-5531.
|
| [27] |
Raschi E, Testoni C, Bosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies[J]. Blood, 2003, 101(9):3495-500.
|
| [28] |
Prinz N, Clemens N, Strand D, et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells[J]. Blood, 2011, 118(8):2322-2332.
|
| [29] |
Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo[J]. Blood, 2009, 114(14):3074-3083.
|
| [30] |
Urbanus RT, Pennings MT, Derksen RH, et al. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′[J]. J Thromb Haemost, 2008, 6(8):1405-1412.
|
| [31] |
Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome[J]. Blood, 2011, 117(4):1408-1414
|
| [32] |
Allen KL, Fonseca FV, Betapudi V, et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies[J]. Blood, 2012, 119(3):884-893.
|